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REfERENCE PRICING fOR LAbORATORy TESTS IN THE UNITED STATES: IMPACT 
ON PRICES AND SPENDING
Robinson J, Brown T, Whaley C
University of California, Berkeley, Berkeley, CA, USA
Objectives: This study examines the impact of reference pricing on the price 
and spending for in vitro laboratory tests for a large private employer in the United 
States. MethOds: We obtained comprehensive laboratory and medical claims for 
employees of a major US firm from 2009 to 2013. Each claim contained the CPT code for 
the test, the price paid (allowed charge), and the identity and the location of the labora-
tory. We matched lab claims to medical claims for the patients, obtaining information 
on age, gender, diagnoses and co-morbidities (ICD9). Beginning in January 2011, the 
firm limited its payment for 566 in vitro laboratory tests to the 60th percentile in the 
price distribution for each test across national laboratories, hospital-based laboratories, 
and freestanding local laboratories. Reference-priced tests generated 99,225 individual 
patient assays and insurance claims. Another 247 types of in vitro tests were exempted 
from reference pricing; these generated 33,480 individual patient assays and insurance 
claims. We used difference-in-difference multivariable regression analysis (GLM with log 
link and gamma distribution) to measure the rate of change in prices paid per test for 
laboratory tests subject to reference pricing, compared to the change in prices paid for 
laboratory tests exempted from reference pricing. Results: Reference pricing led to a 
17.8% (p< .001) reduction in laboratory test prices paid in the first year after implementa-
tion. By the second year, this had increased to 21.6% (p< .001) and by the third year to a 
27.7% (p< .001) reduction. In the three years after implementation of reference pricing, 
the employer saved 18.5% in spending compared to what it would have spent had the 
prices of reference-priced tests continued to increase at the same rate as non-reference 
priced tests. cOnclusiOns: Reference pricing reduces prices paid per test and total 
spending on laboratory tests in the United States.
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THE ASSESSMENT Of VALUE fOR MEDICAL DEVICES: A CASE STUDy ON 
INjECTION TECHNIqUE EDUCATION IN INSULIN DELIVERy
Charter R1, Hopley C2, Su T3, Grima D3, Strauss K4
1Becton Dickinson AG, Allschwil, Switzerland, 2Becton Dickinson, Oxford, Switzerland, 
3Cornerstone Research Group, Burlington, ON, Canada, 4Becton Dickinson, Erembodegem, Belgium
Objectives: Education and product training are critical but overlooked variables in 
the value assessment of medical devices. By example, over 24 million insulin injec-
tions occur daily in Europe, with little knowledge on proper injection technique (IT).1 
This case study illustrates the positive impact of insulin IT education on diabetes 
outcomes, drug consumption and healthcare costs. MethOds: We conducted a 
literature review on diabetes IT. The impact of IT education on adherence, adverse 
events, insulin consumption, and glycemic control were appraised in the context 
of i) Proper device selection; ii) Education, application, and adherence to IT best 
practices; and; iii) adverse event monitoring. Potential healthcare savings from a 
UK NHS perspective were estimated using probabilistic patient simulations based 
on risk equations from the UKPDS study.2 Results: Evidence suggests the clinical 
benefits of IT best practices include 1) better patient acceptability via overall prefer-
ence and lower injection pain (VAS significantly less with shorter needle, sharper 
tips; p< 0.001)3 2), associations between not rotating injection sites (poor IT practice) 
and increased prevalence of lipohypertrophy, > 30% higher insulin consumption 
and worse glycaemic control4 (HbA1c 0.5% higher in patients with lipohypertrophy 
(p= 0.003)5, and 3), lower risk of intramuscular injections with proper device selec-
tion (0.4% – 1.8% for 4 and 5mm needles)6. Another prospective non-controlled 
study, investigating the impact of individualized IT education including site rotation 
and use of short needles, in patients taking insulin for more than 4 years, identified 
a mean HbA1c reduction of 0.58% and reduced insulin consumption by 2 units/day 
within 3 months (both, p< 0.05).7 Over 10 years, savings could range from £12-25 mil-
lion and potential insulin savings of £5 million per 100,000 people. cOnclusiOns: 
The value assessment of medical devices should include HCP/patient education as 
clinical outcomes and cost savings are material. This is exemplified vis-à-vis proper 
education on diabetes IT for people on insulin.
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HEALTHCARE ASSOCIATED INfECTIONS. IMPACT AND COSTS Of DIAGNOSIS 
AND MANAGEMENT Of CLOSTRIDIUM DIffICILE INfECTIONS (CDI). THE 
ExPERIENCE Of A UNIVERSITy HOSPITAL IN ROME
Capozzi C1, Fontana C2, Volpi A1, Lombardi G3, Lisena FP1, Paulon L1, Maurici M1, Visconti G2
1Tor Vergata University, Rome, Italy, 2Tor Vergata University Hospital, Rome, Italy, 3Rareg, Cesano 
Maderno, Italy
Objectives: The diagnosis and treatment of Healthcare Associated Infections (HAI) 
have a significant impact on the care pathways and hospital costs; one of the most 
diffused HAI is Clostridium Difficile (CDI). The study aimed to assess the CDI distri-
bution, related costs and possible areas of saving. MethOds: Patients admitted at 
the TorVergata University Hospital between January and December 2013 presenting a 
CDI diagnosis were identified by analysing the Microbiology Laboratory Information 
Flow. Turn-Around-Time(TAT) was used to assess the efficiency of diagnosis with 
cultural exam and PCR methodologies. Through the analysis of clinical records, the 
CDI distribution in hospital departments and DRGs were examined. The economic 
value associated to each admission was calculated. Results: In the considered 
period, 1769 CDI tests were performed. 752 were valid for the analysis, 170 tests (22%) 
were positive and corresponded to 94 admissions. The TAT analysis showed that the 
PCR allowed saving about three days, compared to the cultural exam. The incidence 
of CDI was 8.2cases per 10,000bed-days/patient. More than half of cases were in: 
General Medicine(27;29%); Gastroenterology(14;15%); casualty department(12;13%); 
Infectious Diseases, respiratory Medicine, onco-haematology(respectively9;10%). 
ALOS was 31.8days (between5-132). The five most frequent DRGs were: DRG-572.
Gastrointestinal and peritoneal infections(n= 10), DRG-576.Septicemia without 
questionnaires based on a 0-7 points Likert scale were delivered to n= 10 subacute 
stroke patients affected by upper limb hemiparesis and n= 23 physiotherapists using 
two different robotic systems (InMotion2, Interactive Motion Technologies, USA and 
Armeo Spring, Hocoma AG, Switzerland). The (i) perceived comfort and effectiveness 
of robot-assisted rehabilitation treatments and (ii) evaluation of human-robot inter-
action was investigated. An economic analysis of costs associated to the introduc-
tion of robotic technology into clinical practice was carried out as well. Results: 
Stroke patients consider the upper limb robot-assisted rehabilitation treatment as 
positive (mean score 5.80±0.89) and 96% of them consider it as safe. An higher score 
associated to the desire of continuing the robotic therapy (mean score 6.30±0.82) 
than that reported by physiotherapists (mean score 5.31±1.66) was found. Positive 
evaluations by patients on usefulness, satisfaction and desire to continue highlight 
the potential effectiveness of the robotic treatment. Results from physiotherapists 
confirm the positive attitude towards robotic technology (mean score 6.12±0.66), 
especially in terms of safety and satisfaction. Direct and indirect costs associated 
to upper limb robot-assisted rehabilitation treatment and traditional manual physi-
otherapy have been found to be comparable. cOnclusiOns: The perceived effec-
tiveness and acceptability of robotic technology for upper limb rehabilitation were 
positively evaluated both by stroke patients and physiotherapists. The initial high 
economic investment in robotic technology should be considered as associated to 
the optimization of healthcare resources. Further analyses on the effects of the 
robot-assisted rehabilitation treatments on the quality of life of patients have to 
be carried out through large multicentric RCTs.
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Objectives: This study aimed at assessing patient preferences for different 
characteristics of Dry Powder Inhalers (DPIs) from patients with asthma and 
chronic obstructive pulmonary (COPD) disease in France, UK, Spain, Germany 
and Netherlands using the discrete choice experiment (DCE) method. MethOds: 
Attributes characterizing DPIs and attribute levels were defined using focus groups 
among asthma and COPD patients and interviews of health care professionals in 
France. Those attributes were ease of use, accurate and easy-to-read dose coun-
ter, dose confirmation, hygiene of the mouthpiece, flexibility of device handling 
and use with breathing difficulties. A fractional factorial design including 3 sets 
of 12 choices was created. Analyses were performed using a ranked ordered logit 
model. Interactions between attributes and asthma/COPD were tested. Results: 
Participants included 601 patients with asthma and 491 with COPD. Asthma and 
COPD patients were on average 43 and 53 years old respectively. Preferences of 
patients with asthma and COPD were largely similar, but the marginal utility of the 
cost attribute was higher in asthma patients, compared to COPD, in three countries. 
In all countries, marginal utilities were highest for ease of use and ability to use 
the inhaler with breathing difficulties. Estimates of willingness to pay (WTP) for an 
inhaler requiring one step to prepare a dose instead of four ranged from € 3.27 (95% 
CI: [2.23;4.32]) in asthma patients in Germany to € 15.14 [-82.43;112.72] in asthma/
Spain. The estimated WTP for ability to use with breathing difficulties ranged from 
€ 2.19 [1.10;3.28] in asthma patients in the Netherlands and € 13.68 [-117.77;145.12] 
in COPD/Spain. The marginal utility of the hygiene of the mouthpiece was not sig-
nificantly different from zero. cOnclusiOns: Despite differences in valuations 
of attributes between counties, two attributes were consistently found to be the 
most important: ease of use and ability to use the inhaler in case of difficulties 
breathing in.
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SUbjECTIVE OUTCOMES wITH bONE CONDUCTION AND MIDDLE EAR 
IMPLANTS fOR PATIENTS wTH CONDUCTIVE OR MIxED HEARING LOSS
Kosaner Kliess M, Zoehrer R, Schlick B, Mariacher M, Urban M
Vibrant MED-EL Hearing Technology GmbH, Innsbruck, Austria
Objectives: With the number of different hearing implants available for indi-
viduals with a conductive/mixed hearing loss (CMHL), it is becoming more and 
more important to demonstrate user needs and benefit, in particular for aiding in 
decision making. The aim of this study was to systematically review the subjective 
outcomes of different hearing implants for individuals with CMHL. MethOds: 
Several databases were searched using a comprehensive search strategy to iden-
tify studies published assessing subjective outcomes with unilateral middle ear 
implantations (MEI), percutaneous bone conduction implants (pBCI) and transcu-
taneous BCIs (tBCI). The search included papers in any language. Non-systematic 
reviews, case reports, letters, editorials; animal, in-vitro and laboratory studies 
and clinical studies with less than 5 cases were excluded. Results: Out of 670 
citations, 22 percutaneous and 7 transcutaneous BCI, plus 10 MEI publications were 
identified (total n= 1106). As many as 20 different questionnaires were applied. All 
devices lead to an improvement in HR-QOL when compared to the unaided condi-
tion. Using HR-QOL measures, outcomes with different pBCIs were in favour of the 
Ponto than the BAHA which was reflected in patient preferences. Comparison of 
pBCI with tBCI and MEI generally showed a similar distribution. Outcomes were 
relatively better with MEI than pBCI on one questionnaire. Outcomes of tBCIs and 
MEIs were also similar on HR-QOL measures, but were slightly in favour of the lat-
ter on a general-health QOL measure (G-QOL). The common HUI G-QOL measure 
was only available for pBCI and MEI users with any type of hearing loss, and results 
were similarly distributed. cOnclusiOns: There are many QOL measures for 
assessing hearing loss, however not many are sensitive at picking up differences 
between hearing implants. The studies identified in the literature, even though 
limited in number and quality, suggest health-related measures to be more sensi-
tive than general health measures.
